Business Wire

MA-REVBIO

15.9.2022 18:48:37 CEST | Business Wire | Press release

Share
RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial

RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite®, the company’s bone adhesive biomaterial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005733/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Dr. Michael R. Norton, BDS, FDS, RCS(Ed), a London-based oral surgeon, noted lecturer, and former President of the Academy of Osseointegration, will serve as the chief investigator for this clinical trial. “I am thrilled to be involved in this clinical trial which builds on the first one I completed earlier this year,” said Dr. Norton. “Since initiating the prior MHRA-approved study in the United Kingdom, RevBio has significantly improved the osteopromotive potential of its biomaterial.”

RevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. In addition, the company has also increased the porosity of the material. Benchtop and animal testing has shown that these changes have improved the material’s biocompatibility with the gingival tissues that surround tooth extraction sites. These formulation changes have also increased the substitution rate of new bone formation without sacrificing the biomaterial’s ability to adhere to bone. In fact, this formulation is more adhesive than the company’s prior dental formulation.

Similar to Dr. Norton’s prior study, this new clinical trial will focus specifically on anterior teeth located in the aesthetic or “smile” zone where the loss of a tooth is highly visible. Patients will receive temporary crowns at the time their implants are placed which will obviate a costly, complex, and lengthy bone grafting process for many patients, greatly accelerating the overall treatment timeframe.

“We are excited to partner again with Dr. Norton who is a thought leader in advancing clinical practice in the field of implant dentistry,” said Alan Pollack, RevBio’s Senior Director of Dental Clinical Operations. “The development of this new formulation has really advanced the company’s ability to tune the biomaterial’s performance to address anatomically-specific requirements.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005733/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blind Sailor Mitsuhiro Iwamoto Redefines the Limits of Possibility Through Technology in a Historic Trans-Pacific Project3.2.2026 04:00:00 CET | Press release

- “HIRO’s CHOICE”: A Solo, Non-Stop Crossing of the Pacific Ocean - Mitsuhiro Iwamoto, a Japanese sailor based in San Diego, who is taking on the world’s first solo, non-stop trans-Pacific crossing by a blind sailor as part of the Blind Sailor Single-Handed Pacific Crossing Project 2027, held a press conference on January 28 (local time) in San Diego, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128531637/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific Project URL: https://hiros-choice.com/ On January 22 (local time), Iwamoto delivered a speech at the World Economic Forum Annual Meeting 2026 (WEF) under the theme “Sailing Through Barriers.” Speaking about the upcoming voyage, he said, “Boundaries are not decided by others. They are transcended by choice.” WEF URL: https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/sessions/sailing-through-barriers/ D

TestMu AI (Formerly LambdaTest) Recognized in Independent Research on Autonomous Testing Platforms, Q4 20252.2.2026 18:24:00 CET | Press release

Research cites AI testing, data generation, and accelerated execution TestMu AI (formerly known as LambdaTest), the world’s first full-stack Agentic Quality Engineering platform, today announced its inclusion in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025, an independent research report evaluating vendors in the autonomous testing market. The report identifies TestMu AI as a cloud-based platform for unified test orchestration and execution. It notes the platform's capabilities in cross-browser testing, real device cloud, and AI-driven automation. Specifically, the research cites TestMu AI’s testing of AI systems across dimensions, providing metrics for accuracy, intent recognition, and hallucination detection with configurable thresholds. Additionally, the report recognizes TestMu AI’s AI-powered test data generation, citing its support for Large Language Models (LLMs), multimodal inputs, and compliance-aligned workflows. The report also noted the company's strong commun

Current Chemicals Launches as Independent Specialty Materials Manufacturer, Building on 75-Year GE Legacy with Backing from Momentum Global Ventures2.2.2026 17:04:00 CET | Press release

Today marks the debut of Current Chemicals, Inc. (CCI) as a fully independent U.S.-based specialty materials manufacturer. Backed by strategic investor Momentum Global Ventures, CCI is charting a bold new path as a trusted partner for materials innovation, custom chemistry, and U.S.-based downstream manufacturing of rare earths and critical materials. The partnership between U.S.-based CCI and Netherlands-based Momentum Global Ventures reflects a strengthening transatlantic alliance at a pivotal moment for global supply chains. This partnership underscores a shared commitment to secure, reliable, and innovation-driven materials infrastructure. Originally the chemical division of GE Lighting, the team behind CCI has served as the quiet force behind groundbreaking technologies for more than 75 years, developing processes and manufacturing advanced materials for displays, lighting, energy storage, and more. As an independent company, CCI is poised to expand its impact across industries de

Laserfiche’s Taylor Grosso Honored as 2026 CRN® Channel Chief2.2.2026 16:00:00 CET | Press release

Laserfiche — the leading SaaS provider of intelligent content management — announced today that CRN® — a brand of The Channel Company — has selected Taylor Grosso, senior director, channel, Americas, as a 2026 CRN® Channel Chief. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. Grosso oversees Laserfiche’s Americas channel sales team, including the U.S., Canada, and Latin America, focusing on empowering Laserfiche Solution Providers to stay competitive as the market evolves. As more organizations seek out AI-powered tools to enhance productivity, Grosso prepares partners with the resources they need to quickly learn and sell Laserfiche’s industry-leading AI-powered document management solutions. By working closely with partners on building targeted business plans, Grosso and his team enable faster customer adoption of AI while driving revenue growth. “Over the past year,

Conga Completes Acquisition of PROS B2B Business2.2.2026 15:55:00 CET | Press release

Redefines Commercial Excellence for Enterprises with a Clear Path from Price to Signature Conga, a leader for AI-powered innovation in configure, price, quote (CPQ), contract lifecycle management (CLM), and document automation, today announced it has completed the acquisition of the B2B business of PROS Holdings, Inc (“PROS”) from certain investment funds affiliated with Thoma Bravo, the world’s largest software-focused investment firm. This transaction unites two industry leaders to help enterprises maximize revenue, reduce risk, and improve profitability. By bringing together AI-driven pricing optimization, configuration, quoting, and contracting capabilities, the combined company creates a differentiated enterprise platform that connects the commerce chain and enables end-to-end revenue orchestration from price to signature. The expanded Conga leadership team will continue to be led by CEO Dave Osborne. “To operate as connected, intelligent businesses, enterprises need a commerce ch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye